Zeke Capital Advisors Lowered Its Biogen Com (BIIB) Stake; Imperial Metals (TSE:III) Had 1 Bullish Analysts

June 20, 2018 - By Dolores Ford

Biogen Inc. (NASDAQ:BIIB) Logo

Among 5 analysts covering Imperial Metals Corporation (TSE:III), 1 have Buy rating, 2 Sell and 2 Hold. Therefore 20% are positive. Imperial Metals Corporation had 21 analyst reports since August 17, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Sector Perform” rating and $7 target in Friday, July 22 report. Canaccord Genuity downgraded the shares of III in report on Wednesday, January 18 to “Sell” rating. The stock has “Hold On Valuation” rating by TD Securities on Thursday, January 19. RBC Capital Markets initiated Imperial Metals Corporation (TSE:III) rating on Wednesday, December 9. RBC Capital Markets has “Sector Perform” rating and $8 target. The firm has “Hold” rating given on Wednesday, January 4 by TD Securities. The stock of Imperial Metals Corporation (TSE:III) earned “Underperform” rating by Scotia Capital on Tuesday, October 17. The rating was maintained by Scotia Capital on Friday, January 20 with “Underperform”. See Imperial Metals Corporation (TSE:III) latest ratings:

Zeke Capital Advisors Llc decreased Biogen Inc Com (BIIB) stake by 30.42% reported in 2018Q1 SEC filing. Zeke Capital Advisors Llc sold 1,659 shares as Biogen Inc Com (BIIB)’s stock declined 1.31%. The Zeke Capital Advisors Llc holds 3,795 shares with $1.04M value, down from 5,454 last quarter. Biogen Inc Com now has $62.74 billion valuation. The stock increased 1.81% or $5.3 during the last trading session, reaching $297.34. About 1.03M shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 13.14% since June 20, 2017 and is uptrending. It has outperformed by 0.57% the S&P500. Some Historical BIIB News: ; 24/04/2018 – BIOGEN INC – QTRLY SHR $5.54; 15/05/2018 – Bridgewater Adds Biogen, Exits Costco, Buys More Newfield: 13F; 01/05/2018 – Biogen to Make One-Time $50M Payment to Neurimmune; 05/04/2018 – Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe; 09/03/2018 – Skyland Analytics Appoints James C. Mullen, Former Biogen and Patheon CEO, to Advisory Board; 24/04/2018 – BIOGEN INC – QTRLY TYSABRI REVENUE OF $$462 MLN VS. $545 MLN REPORTED LAST YEAR; 24/04/2018 – Biogen Reports Quarterly Revenues of $3.1 Billion; 05/04/2018 – AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023; 12/03/2018 – Biogen to Pay $75 Million Upfront Plus Potential Milestones Up to $515 Million and Royalties; 05/04/2018 – BIOGEN – UNDER TERMS OF AGREEMENT, ABBVIE WILL GRANT PATENT LICENSES FOR USE AND SALE OF IMRALDI IN EUROPE, ON A COUNTRY-BY-COUNTRY BASIS

Investors sentiment decreased to 1.07 in Q1 2018. Its down 0.10, from 1.17 in 2017Q4. It dived, as 69 investors sold BIIB shares while 305 reduced holdings. 92 funds opened positions while 308 raised stakes. 178.22 million shares or 1.35% less from 180.65 million shares in 2017Q4 were reported. Northcoast Asset Mgmt Ltd Llc reported 2.04% in Biogen Inc. (NASDAQ:BIIB). Ls Inv Lc has 0.11% invested in Biogen Inc. (NASDAQ:BIIB). Fort Washington Invest Advisors Oh has invested 1.22% in Biogen Inc. (NASDAQ:BIIB). California-based Bedell Frazier Counseling Ltd Limited Liability Company has invested 2.5% in Biogen Inc. (NASDAQ:BIIB). Grandfield & Dodd Ltd reported 0.04% in Biogen Inc. (NASDAQ:BIIB). State Treasurer State Of Michigan holds 0.14% or 62,277 shares in its portfolio. Bb&T Securities Limited Com, a Virginia-based fund reported 13,174 shares. Legacy Private owns 0.22% invested in Biogen Inc. (NASDAQ:BIIB) for 6,733 shares. Keybank Association Oh invested in 0.03% or 17,954 shares. Nordea Invest Ab reported 0.28% stake. The Massachusetts-based American And Mgmt Company has invested 0.83% in Biogen Inc. (NASDAQ:BIIB). Cambridge Inv Inc has 0.02% invested in Biogen Inc. (NASDAQ:BIIB) for 5,185 shares. Wesbanco National Bank & Trust, West Virginia-based fund reported 1,595 shares. Moreover, Stone Ridge Asset Mngmt Llc has 0.12% invested in Biogen Inc. (NASDAQ:BIIB) for 7,500 shares. The United Kingdom-based Rathbone Brothers Pcl has invested 0.01% in Biogen Inc. (NASDAQ:BIIB).

Since January 9, 2018, it had 1 insider purchase, and 5 insider sales for $10.09 million activity. Sandrock Alfred sold $386,712 worth of stock or 1,294 shares. PANGIA ROBERT W also sold $1.92M worth of Biogen Inc. (NASDAQ:BIIB) shares. The insider DENNER ALEXANDER J bought $12.96 million.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Fool.com which released: “Here’s Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle” on June 18, 2018, also Nasdaq.com with their article: “Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018” published on June 19, 2018, Fool.com published: “Don’t Get Too Excited About PTC Therapeutics (Yet)” on June 20, 2018. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Seekingalpha.com and their article: “PTC Therapeutics’ risdiplam shows positive effect in SMA study; shares up 36% premarket” published on June 18, 2018 as well as Fool.com‘s news article titled: “Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today” with publication date: June 18, 2018.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on July, 24. They expect $5.22 earnings per share, up 3.57% or $0.18 from last year’s $5.04 per share. BIIB’s profit will be $1.10 billion for 14.24 P/E if the $5.22 EPS becomes a reality. After $6.05 actual earnings per share reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -13.72% negative EPS growth.

Among 33 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 25 have Buy rating, 0 Sell and 8 Hold. Therefore 76% are positive. Biogen Idec Inc. had 133 analyst reports since July 23, 2015 according to SRatingsIntel. Goldman Sachs maintained Biogen Inc. (NASDAQ:BIIB) on Tuesday, October 24 with “Buy” rating. Raymond James initiated Biogen Inc. (NASDAQ:BIIB) on Tuesday, September 1 with “Strong-Buy” rating. The stock has “Hold” rating by Robert W. Baird on Thursday, January 25. As per Tuesday, April 24, the company rating was maintained by SunTrust. The firm has “Outperform” rating given on Monday, November 6 by BMO Capital Markets. The rating was maintained by Bernstein on Tuesday, November 28 with “Buy”. The firm earned “Buy” rating on Thursday, February 25 by Citigroup. H.C. Wainwright maintained Biogen Inc. (NASDAQ:BIIB) on Wednesday, July 26 with “Buy” rating. The firm has “Buy” rating given on Thursday, January 7 by Standpoint Research. Robert W. Baird maintained Biogen Inc. (NASDAQ:BIIB) rating on Thursday, September 28. Robert W. Baird has “Hold” rating and $290.0 target.

Zeke Capital Advisors Llc increased General Dynamics Corp Com (NYSE:GD) stake by 4,669 shares to 7,468 valued at $1.65M in 2018Q1. It also upped Morgan Stanley Com New (NYSE:MS) stake by 8,385 shares and now owns 37,551 shares. Visa Inc (NYSE:V) was raised too.

Investors sentiment decreased to 1.18 in Q1 2018. Its down 0.42, from 1.6 in 2017Q4. It dived, as 3 investors sold Imperial Metals Corporation shares while 19 reduced holdings. 6 funds opened positions while 20 raised stakes. 17.81 million shares or 5.07% more from 16.95 million shares in 2017Q4 were reported. Dimensional Fund Advisors L P invested 0% in Imperial Metals Corporation (TSE:III). Renaissance Lc invested in 0.01% or 1.92M shares. Geode Mgmt Limited Liability Company invested in 218,742 shares or 0% of the stock. 1,700 are owned by Earnest Ltd Co. 27,121 are owned by Ancora Limited Com. Moreover, Bancorporation Of Ny Mellon Corporation has 0% invested in Imperial Metals Corporation (TSE:III). Moreover, Weber Alan W has 2.01% invested in Imperial Metals Corporation (TSE:III). Creative Planning holds 0% or 33,600 shares. Moreover, Blair William & Il has 0.04% invested in Imperial Metals Corporation (TSE:III). Citigroup Incorporated invested in 82,409 shares. Barclays Public Limited Co holds 0% or 6,893 shares in its portfolio. Punch And Associates Inv Mgmt holds 0.37% or 1.01 million shares in its portfolio. Moreover, Mcgowan Gru Asset Mngmt has 0.05% invested in Imperial Metals Corporation (TSE:III) for 62,843 shares. Price T Rowe Assoc Md holds 0% of its portfolio in Imperial Metals Corporation (TSE:III) for 18,749 shares. State Street Corporation accumulated 481,552 shares.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: